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Selective estrogen receptor modulator
Vaginal atrophy
Women  without uterus
a  b  s  t  r  a  c  t
Objective:  To examine  the long-term  safety  of  oral  ospemifene,  a non-estrogen  tissue-selective  estrogen
agonist/antagonist,  for the treatment  of  moderate  to  severe  dyspareunia,  a  symptom  of  vulvar  and  vaginal
atrophy  (VVA)  due  to menopause.
Study  design:  This  multicenter,  long-term,  open-label,  safety  extension  study  was  conducted  in women
without  a  uterus  aged 40–80  years  (N =  301)  who  received  oral  ospemifene  60  mg/day  for  52  weeks.
Participants  either  continued  their  60-mg/day  ospemifene  dose  from  the initial  12-week  pivotal  efficacy
study  or  switched  from  blinded  placebo  or ospemifene  30 mg/day  to open-label  ospemifene  60  mg/day.
The  52-week  open-label  extension  period  plus  initial  12-week  treatment  period  totaled  up to  64 weeks
of  ospemifene  exposure.  A 4-week  posttreatment  follow-up  ensued  (68 weeks  total).
Main  outcome  measures:  Safety  assessments  included  adverse  events,  laboratory  studies,  physical  and
gynecologic  examination,  vital signs,  breast  palpation,  and  mammography.
Results:  Most  treatment-emergent  adverse  events  (TEAEs)  during  the extension  study  were  mild  or
moderate  in  severity.  The  most  common  TEAE  related  to study  drug  was  hot  flushes  (10%;  leading to
discontinuation  for 2%  of  patients).  One  serious  TEAE,  a non-ST-elevation  myocardial  infarction  in  a
patient  with  pre-existing  cardiac  disease,  was  considered  possibly  related  to study  medication.  One  mild
breast-related  TEAE,  considered  unrelated  to study  drug,  was  ongoing  at study  completion.  There  were
no instances  of pelvic  organ  prolapse,  incontinence,  venous  thromboembolism,  fractures,  breast  cancers
or death.  No clinically  significant  adverse  changes  were  observed  in other  safety  parameters.
Conclusions:  Ospemifene  is  clinically  safe  and  generally  well  tolerated  in  postmenopausal  patients  with
dyspareunia,  a  symptom  of  VVA.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  All  rights  reserved.
1. Introduction
Vulvar and vaginal atrophy (VVA) is a chronic and often progres-
sive condition that affects approximately 50% of postmenopausal
women [1–5]. Despite the high prevalence of VVA, this condi-
tion is often undiagnosed or inadequately treated [1–3]. Currently
available treatment options include over-the-counter products
(lubricants and moisturizers) that may  provide some temporary
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non-commercial use, distribution, and reproduction in any medium, provided the
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symptom relief, but do not treat the physiological changes under-
lying VVA, which can lead to the development of symptoms such as
dyspareunia [6–8]. Other treatment options include vaginal estro-
gen therapies, which are recommended to be used at the lowest
effective dose for the shortest duration consistent with treatment
goals and risks for the individual woman [4,9–12]. Given the limited
number of options, additional treatment choices for physicians and
patients are desirable [1,2].
Ospemifene, a tissue-selective estrogen agonist/antagonist (also
known as a selective estrogen receptor modulator, SERM), is the
first non-estrogen oral prescription alternative to estrogen ther-
apies for the treatment of moderate to severe dyspareunia, a
symptom of VVA due to menopause [13,14]. Ospemifene has mul-
tiple tissue-specific effects. Initial preclinical studies of ospemifene
on bone structure and strength demonstrated that ospemifene
has stimulatory effects on bone [15]. Additional preclinical stud-
ies showed that ospemifene treatment has anti-estrogenic effects
0378-5122/$ – see front matter © 2014 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.
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in vitro and in vivo in human MCF-7 breast cancer cells [16,17].
To date, clinical trials on bone and breast endpoints have not
been performed. Ospemifene has neutral to antagonistic activity
on endometrial tissue [15]. The profile of ospemifene in clinical
trials and in preclinical studies demonstrated beneficial effects on
physiological changes in the vagina that are associated with VVA,
while having selective agonist/antagonist effects in other tissues,
and resulting in improvement of symptoms of dyspareunia in post-
menopausal women [18,19].
In short- and long-term studies of postmenopausal women,
ospemifene was shown to be effective for the treatment of
moderate to severe symptoms associated with VVA [20–23]. In
a 12-week, randomized, double-blind study in postmenopausal
women (N = 826) comparing ospemifene 30 mg/day and 60 mg/day
with placebo, ospemifene 60 mg/day demonstrated statistically
significant improvement over placebo for all co-primary endpoints,
including improvement from Baseline (“Baseline” refers to Day 1
of the initial 12-week study) in the percentages of superficial and
parabasal cells (p < .001 for both), vaginal pH (p < .001), and severity
of the most bothersome symptoms of VVA, including dyspareunia
(p = .023) or dryness (p = .021) [20]. Ospemifene was generally well
tolerated. The most frequently reported adverse events (AEs) were
hot flushes, which were generally mild or moderate in severity and
resulted in a low rate of discontinuation. Other commonly reported
AEs included urinary tract infections and headaches. In addition to
the 1-year safety extension study of ospemifene 60 mg  reported
herein, a separate 40-week safety extension was  conducted in a
cohort of women with an intact uterus (n = 180) who continued the
randomized double-blind treatment that they had been assigned
in the initial 12-week study (ospemifene 30 mg/day, ospemifene
60 mg/day, or placebo) [21].
During the extension period in the study of women  with
an intact uterus, no clinically significant adverse changes were
observed from safety assessments, which included endometrial
ultrasound and biopsy assessments; gynecologic examinations,
mammograms, and Papanicolaou tests; physical examinations;
vital signs; and safety laboratory values. Similar to the initial 12-
week study, the most frequently reported treatment-related AE
was hot flushes, which resulted in few discontinuations. Since
several SERMs in development were associated with a significant
4-fold or greater increased incidence of pelvic organ prolapse and
incontinence, treatment-emergent AEs (TEAEs) of this type are of
particular interest, especially in a hysterectomized cohort [24,25].
No increased incidences of prolapse or incontinence were observed
in hysterectomized women while taking ospemifene during this
extension study. This report presents findings from a 52-week,
open-label extension assessing the long-term safety of ospemifene




This multicenter, open-label, long-term safety extension study
enrolled women without a uterus (ClinicalTrials.gov identifier:
NCT01586364) who had participated in the initial 12-week, Phase
3, efficacy and safety study of ospemifene for the treatment of
VVA in postmenopausal women (NCT00276094) [20] (Fig. 1A).
The details of this initial study have been described elsewhere;
however, a general summary is provided here. A randomized,
double-blind study of 826 postmenopausal women with and
without a uterus were randomized to receive ospemifene 30 or
60 mg/day or placebo (1:1:1) for 12 weeks. An additional, sepa-
rate, long-term (52-week) extension study of women with a uterus
has been completed and is described elsewhere [21]. This exten-
sion study included 301 women  without a uterus. The duration
of the open-label treatment extension was  52 weeks. During this
extension, all patients were treated with ospemifene 60 mg/day
regardless of treatment assignment in the initial 12-week study.
The safety extension study concluded with a 4-week follow-up
period. Thus, the duration of treatment plus the posttreatment
follow-up period totaled 68 weeks (Fig. 1B).
The results of a separate long-term safety extension study
(NCT01585558) of 180 postmenopausal women with an intact
uterus, who  completed the initial 12-week study and remained on
double-blind treatment with ospemifene or on placebo, have been
reported previously [21].
2.2. Patient population
All participants who entered the present open-label safety
extension study were required to have completed the initial 12-
week study. A detailed account of inclusion and exclusion criteria
for the initial study has been reported previously [20]. Briefly,
the women were required to be 40–80 years of age and post-
menopausal (defined as at least 6 weeks elapsed since a bilateral
oophorectomy, or, in the case of hysterectomized women with
intact ovaries, follicle-stimulating hormone [FSH] levels ≥40 IU/L).
Participants were also required to have the following signs and
symptoms of VVA: ≤5% superficial cells on a vaginal smear (Mat-
uration Index); vaginal pH >5.0; and at least 1 moderate or severe
symptom of VVA (such as dyspareunia or vaginal dryness).
Exclusion criteria were as follows: body mass index (BMI)
≥37 kg/m2; systolic blood pressure ≥180 mm Hg or diastolic blood
pressure ≥100 mm Hg; clinically relevant abnormalities in safety
laboratory tests (hematology, chemistry, urinalysis, coagulation
parameters, serum lipid levels, and hormone levels) or electro-
cardiogram; clinically significant abnormal findings on complete
pelvic examination, breast examination, or mammogram; suspi-
cion or history of any malignancy within 10 years; or use of any
hormone therapy (unless a sufficient washout period preceded any
procedure).
Women  who met  the study criteria and had completed the initial
12-week study were eligible for the present 52-week extension
study. Participants were excluded from the extension study if there
were clinically significant abnormal findings at the Week 12 visit for
the initial study or if they had any physical or psychiatric condition
that could have interfered with their ability to adhere to the study
procedures.
Written informed consent, including agreement to follow dos-
ing regimens and attend all study visits, was  obtained prior to
enrollment. All participants received treatment with open-label,
oral ospemifene 60-mg tablets, which were taken once daily in
the morning with food. Institutional Review Board (IRB) approval
was obtained for each study site, with a central IRB responsible for
the initial and continuing review and approval of the clinical study
and for complying with the requirements of section 21 of the Code
of Federal Regulations (CFR), Part 56. The study was conducted in
accordance with the guidelines of Good Clinical Practice, the Dec-
laration of Helsinki, and all applicable local regulations. This study
was conducted in accordance with the ethical principles originating
from the Declaration of Helsinki and current Good Clinical Practices
and in compliance with local regulatory requirements and 21 CFR
312.
2.3. Safety assessments
A summary of safety assessments is provided in Fig. 2. AEs
were documented at each study visit, and participants were
instructed to spontaneously report any AEs occurring between
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Fig. 1. (A) Study disposition (intent-to-treat population). aThe number of participants without a uterus. bThe number of participants with a uterus (reported separately) [21].
cLost to follow-up; participant decision/consent withdrawal; adverse event; major protocol violation; participant used a concomitant medicinal product that may compromise
safety  or efficacy evaluations; significant noncompliance with treatment or study procedures; and any other reason as judged by the investigator. dOne  participant without a
uterus  on ospemifene 30 mg/day signed an informed consent form but did not enroll in the extension study. eOne participant without a uterus on ospemifene 60 mg/day was
moved to the extension study but did not sign an informed consent form and was  not enrolled. fAll participants without a uterus were treated with ospemifene 60 mg/day
(patients who  had been randomized to receive ospemifene 30 mg or placebo in the initial 12-week study were switched to ospemifene 60 mg). (B) Timeline of the 52-week
safety  extension of a 12-week efficacy and safety study in postmenopausal women. aPatients in the extension study included only those without an intact uterus. b“Baseline”
in  the 52-week extension study for safety and visual evaluation parameters refers to Baseline in the initial 12-week study. cOr discontinuation. dThe total treatment period
for  the safety study was 52 weeks, followed by a 4-week posttreatment follow-up period (68 weeks total, including the initial study).
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Fig. 2. Summary of assessments. aPapanicolaou smear was performed on women  with an intact cervix at Week 52. BMI, body mass index.
visits throughout the study period. All AEs reported during the
study were considered TEAEs, defined as any unfavorable event
(including laboratory value, symptom, or disease) associated with
the study drug or any other medicinal product taken by the par-
ticipant. Significant worsening in health status or existing diseases
observed during physical examinations were also considered AEs. A
treatment-emergent serious AE (TESAE) was defined as any unto-
ward medical event that resulted in death, was  life threatening,
required inpatient hospitalization or prolonged an existing hospi-
talization, or resulted in persistent or significant disability and/or
incapacity.
The clinical examinations used to evaluate safety included
physical examination and vital signs, breast palpation and mammo-
grams, and gynecologic examinations. During visual examination
of the vagina, specific observations were made for vaginal dryness,
petechiae, pallor, friability, and redness of the mucosa. Each of these
vaginal assessments was rated on the following 4-point scale: 0,
none; 1, mild; 2, moderate; and 3, severe. Key laboratory assess-
ments included serum lipid levels, hormone levels, and coagulation
parameters.
2.4. Statistical methods
The primary objective of this study was to assess the long-term
safety of 60-mg/day doses of ospemifene in the treatment of VVA in
postmenopausal women without a uterus. The analysis character-
ized changes from Baseline in safety parameters. (As noted earlier,
Baseline in the extension study refers to Baseline in the initial 12-
week study.) All analyses were performed using SAS® Release 8.2
(SAS Institute Inc, Cary, NC) and were conducted in the intent-
to-treat (ITT) population, defined as all study participants who
received at least 1 dose of study medication. Descriptive statistics
were used unless otherwise noted. For continuous variables, data
were summarized, including the mean, standard deviation (SD),
median, and minimum and maximum values. Categorical variables
were summarized, including frequencies and percentages.
Demographic and Baseline characteristics were summarized
using all data available for each variable. The study parameters
were summarized using observed cases (OC) and the last obser-
vation carried forward (LOCF) method for available data at Week
26 ± 6 weeks and at Week 52 ± 6 weeks. Subjects were excluded
from summaries where data were missing for a given parameter.
AEs were coded by the Medical Dictionary for Regulatory Activities
(MedDRA) version 9.1 and tabulated by system organ class (SOC),
preferred term (PT), relationship to study drug, and severity. The
most frequently occurring AEs, serious AEs, and AEs leading to study
drug discontinuation were also summarized by SOC and PT.
3. Results
3.1. Participant disposition and demographics
A total of 379 participants who completed the initial 12-week
study had had a total hysterectomy and thus were eligible to enter
the safety extension study. For this investigation, 301 women were
enrolled and included in the ITT population. No details were col-
lected on the 78 women who  elected not to enroll. Of  these 301
participants, 184 (61%) completed the final treatment period (Week
52) of the extension (Fig. 1A). Baseline demographics and charac-
teristics of the ITT population are shown in Table 1. The majority
Table 1




Age (years), mean (SD) 59.4 (6.7)
BMI  (kg/m2), mean (SD) 26.9 (4.4)
Race, n (%)
White 278 (92.4)
Black or African American 11 (3.7)
Asian 6 (2.0)
American Indian/Alaskan Native 3 (1.0)
Other 3 (1.0)
BMI, body mass index; SD, standard deviation.
a Demographic information was  derived from the initial study of safety and effi-
cacy.
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Table 2
Summary of TEAEs during the 52-week extension study.




Serious TEAE 13 (4.3)
Most frequent TEAEsc
Sinusitis 24 (8.0)
Urinary tract infection 26 (8.6)
Hot flushes 31 (10.3)
TEAE leading to discontinuation 34 (11.3)
TEAE, treatment-emergent adverse event.
a Does not include TEAEs that were ongoing from the 12-week pivotal study.
b Includes participants in the intent-to-treat population.
c Occurred in ≥5% of patients in any prior treatment group.
of participants were white (92.4%), the mean age was 59 years
(range, 41–80 years), and the mean BMI  was 26.9 kg/m2 (range,
17.4–38.0 kg/m2).
Among the ITT population, the mean adherence rate to the study
drug was 86.7% and the mean duration of treatment was 309.2 days.
A total of 117 participants (38.9%) discontinued treatment, most
commonly because of withdrawal of consent (13.2%), followed by
an AE (12.3%) and lost to follow-up (5.6%) (Fig. 1A). See below rea-
sons for discontinuation and refer to Table 2.
3.2. Safety and tolerability
3.2.1. Treatment-emergent adverse events
A summary of TEAEs that developed in the ITT population dur-
ing the 52-week extension study is provided in Table 2. Of the
301 participants, 220 (73.1%) experienced at least 1 TEAE during
the extension study. Most TEAEs were rated mild or moderate in
severity, and the most frequently reported TEAEs were hot flushes,
sinusitis, and urinary tract infection; among these, only hot flushes
was study drug-related (Table 2).
A total of 19 TESAEs were experienced by 13 participants. Only 1
TESAE was considered by the investigators to be possibly related to
the study drug: a non-ST-elevation myocardial infarction in a 60-
year-old woman with pre-existing cardiac disease (requiring stent
placement 2.5 years before study enrollment) and a long history
of type 2 diabetes mellitus, hyperlipidemia, and hypertension. A
TESAE of hemorrhagic stroke, reported in 1 participant who  com-
pleted the 12-week study on the 30-mg dose of ospemifene and
had entered the extension study, experienced the cerebrovascular
accident after 21 days on the 60-mg dose. The participant, who was
concomitantly receiving sumatriptan, recovered and the event was
considered by the investigator as unlikely related to ospemifene.
Thirty-four participants discontinued treatment due to a TEAE that
was not ongoing from the initial 12-week study. TEAEs that led to
discontinuation in ≥2 participants included hot flushes (n = 6), nau-
sea (n = 3), headache (n = 3), muscle spasms (n = 2), hyperhidrosis
(n = 2), and rash (n = 2). All 6 participants who discontinued due to
hot flushes had entered the initial 12-week study with hot flushes
at Baseline. There was 1 case of superficial thrombophlebitis that
resolved after 1 day of heparin treatment, but there were no cases
of deep venous thromboembolism. There were no occurrences of
pelvic organ prolapse, incontinence, fractures, breast cancer, and
no deaths.
3.2.2. Clinical laboratory evaluations
No clinically significant changes occurred from Baseline to Week
26 or Week 52 in the levels of total cholesterol, low-density
lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL)
cholesterol. Mean (±SD) total cholesterol declined from 213.2
(±38.2) mg/dL at Baseline to 208.3 (±32.8) mg/dL at Week 52;
Table 3
Visual examination of the vagina in observed cases (OC)a.













Vaginal dryness in mucosa −1.4 (±0.87) −1.5 (±0.88)
Petechiae −0.6 (±0.86) −0.6 (±0.90)
Pallor −1.0 (±0.95) −1.2 (±0.95)
Friability −0.8 (±0.89) −0.8 (±0.91)
Vaginal redness in mucosa −0.6 (±0.92) −0.8 (±0.89)
BL, Baseline; SD, standard deviation.
Each characteristic was assessed on a 4-point scale: 0, none; 1, mild; 2, moderate;
and 3, severe.
a Data collected from participants who discontinued the trial within 6 weeks of
the  final treatment visit (Week 52) were included in the OC analysis.
mean LDL cholesterol declined from 121.7 (±31.6) mg/dL to 116.1
(±27.0) mg/dL; and mean HDL cholesterol was virtually unchanged,
increasing slightly from 63.4 (±15.6) mg/dL to 63.8 (±16.7) mg/dL.
Mean triglycerides increased from 130.3 (±76.8) mg/dL to 135.5
(±65.3) mg/dL. A minor decrease in the mean fibrinogen levels and a
minor increase in the mean protein-S antigen levels were observed
at Weeks 26 and 52. Overall, the mean levels of other coagula-
tion parameters remained essentially unchanged, and no AEs were
reportedly related to coagulation parameters.
No clinically meaningful changes from Baseline in mean chem-
istry values were apparent at Week 26 or Week 52 using OC or
LOCF methodology. Among OC, the levels of FSH and luteinizing
hormone (LH) had decreased by Week 26 and Week 52, whereas
sex hormone-binding globulin (SHBG) and total testosterone had
increased, similar to the patterns of change observed in the initial
12-week study. The mean (±SD) changes from Baseline to Week
52 in FSH, LH, SHBG, and total testosterone were −15.9 (±13.6),
−1.7 (±6.7), 72.7 (±39.1), and 2.2 (±5.2), respectively. No major
changes were observed in mean estradiol (E2) or free testosterone
values; the majority of E2 values were below the limit of detection
(10 mg/mL).
3.2.3. Clinical signs and symptoms
No clinically significant changes were observed in the mean
changes in vital signs at Weeks 26 or 52 of the extension study.
There were a total of 9 TEAEs categorized as being related to the
breast; however, only 4 were considered truly breast related, all of
which were considered mild or moderate in severity. One patient
in the ospemifene group had a breast-related TEAE (breast mass)
that was ongoing at the end of the study and at the 4-week follow-
up (Visit 4). Further follow-up of this patient found that results
by mammography, conducted as part of routine care during the 5
years after study termination, were reported as normal. This AE was
assessed as mild and unlikely related to the study drug.
Efficacy was  assessed by visual examination of the vagina and
showed improvements from Baseline in the mean severity scores
for all 5 parameters (vaginal dryness, petechiae, pallor, friability,
and redness of the mucosa) at Weeks 26 and 52 of the extension
study (Table 3). Among participants assessed at Week 52, ≥93%
had scores of 0 (“none”) or 1 (“mild”) for all visual examination
parameters: vaginal dryness (93%), petechiae (96.5%), pallor (93%),
friability (97%), and redness of the mucosa (96%), with the great-
est percentage improvement from Baseline in number of patients
scored as having “none” or “mild” for dryness by Week 52 (29.3%
vs. 93.0%, respectively) (Fig. 3).
The percentage of patients assessed as “severe” (score = 3) at
Baseline was  22.3% for vaginal dryness, 3.3% for petechiae, 13.3%
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Fig. 3. Visual evaluation of the vagina. Percentage of participants with a score of
0  (“none”) for each parameter, as assessed by visual evaluation of the vagina at
Baseline and at Week 52 (observed cases). Data collected from subjects who discon-
tinued the trial within 6 weeks of the final treatment visit (Week 52) were included
in the observed cases analysis. Examination scoring scale: 0, none; 1, mild; 2, mod-
erate; and 3, severe. (Baseline: N = 300 patients on ospemifene 60 mg/day; Week 52:
N  = 198 patients on ospemifene 60 mg/day.). The number in parentheses denotes the
number of subjects.
for pallor, 4.7% for friability, and 4.7% for redness of the mucosa; at
Week 52, the percentages were <0.5% for all parameters. Likewise,
the percentage of patients assessed as “none” (score = 0) increased
substantially between Baseline and Week 52 for all 5 parameters
assessed by visual examination of the vagina.
4. Discussion
In this safety extension study of postmenopausal women with
moderate to severe VVA who had previously undergone a hysterec-
tomy, ospemifene 60 mg/day for up to 64 weeks was  generally well
tolerated. Consistent with previous studies, most AEs were mild or
moderate in severity [20,21,23]. Although hot flushes were among
the most common TEAEs in the extension study (observed in 10% of
women), they were associated with a low rate of discontinuation
(2%) and were experienced in participants with hot flushes upon
entry into the initial 12-week study. Similar to findings in the 12-
week study and the long-term follow-up of women with an intact
uterus, there were no clinically significant adverse changes in lipids,
coagulation parameters, or hormone levels among the women  with
no uterus [20,21]. Any breast-related TEAEs were considered mild
or moderate in severity. The breast mass resolved in the ospemifene
recipient whose mass was present through the 4-week follow-up
period. Results of mammograms conducted as part of routine care
visits after conclusion of the study were normal.
The effect of SERMs on pelvic organs is not class specific and
each specific compound has different effects on the genitouri-
nary tract. SERMs interact with both estrogen receptors  and 
which are found throughout the urogenital tissue, including the
urethra, levator ani, and anterior vaginal wall, as well as in the
uterosacral ligaments [26–28]. The antagonistic effects of some
SERMs may  impact the continence mechanism and pelvic sup-
port. Development of levomeloxifene for treatment and prevention
of osteoporosis was halted based on high incidence of adverse
effects including a 7% vs. 2% incidence of prolapse over placebo and
17% vs. 4% incidence of incontinence over placebo [25]. Likewise,
development of idoxifene was halted after preliminary observation
indicated an increase of prolapse cases [24,29,30]. Raloxifene and
tamoxifen may  have an effect on prolapse or urinary incontinence
but mixed results are reported [31]. The impact of SERMs on the
pelvic floor and other urogenital tissue is important, particularly for
women with hysterectomy given that hysterectomy may  increase
the risk for prolapse and incontinence [32,33]. In this 52-week
extension study, no increased incidences of prolapse or incon-
tinence were observed in hysterectomized women while taking
ospemifene.
Ospemifene has demonstrated a unique tissue-selective activ-
ity profile suitable for its indicated use in postmenopausal women
with VVA. Although the current study focused on safety, visual
evaluations of the vagina showed sustained clinical improvements
(e.g., a 2-level change, from “severe” to “none,” “severe” to “mild,”
or “moderate” to “none”) from Baseline in all 5 characteristics
examined. Similarly, a greater percentage of patients at Week 52
compared to Baseline were assessed as having no finding of vaginal
dryness (67.7% vs. 2.3%), petechiae (77.8% vs. 40.7%), pallor (55.1%
vs. 9.3%), friability (85.4% vs. 37.3%), or redness of the mucosa (67.2%
vs. 20.0%), respectively. The clinical observations in the present trial
are consistent with results of the initial 12-week study and another
long-term safety study and further demonstrate pelvic floor safety
and a restoration of tissue quality and integrity in ospemifene-
treated hysterectomized patients for up to 52 weeks [20,21]. The
open-label design of the current trial could be considered a limita-
tion of the study results.
5. Conclusions
Once-daily treatment with ospemifene 60 mg  was  effective
and generally well tolerated in this long-term follow-up study of
postmenopausal women without a uterus. Safety findings from
this study are consistent with those of other Phase 3 studies in
women with an intact uterus. Most AEs were generally consid-
ered to be mild to moderate in severity. Visual evaluations of the
vagina showed sustained clinical improvement for all parameters
throughout the 52-week extension study with a greater percent-
age of patients assessed as having no symptoms compared with
Baseline. Additionally, no incidents of prolapse or incontinence
TEAEs were observed for this group of hysterectomized women.
Ospemifene, an estrogen agonist/antagonist with tissue-selective
effects, is the first non-estrogen oral therapy suitable for its indi-
cated use in the treatment of moderate to severe dyspareunia, a
symptom of VVA. At the 60-mg dose for 52–64 weeks, ospemifene
was safe and clinically effective in improving the symptoms of
vaginal dryness and dyspareunia associated with VVA for women
without a uterus.
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